Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients

• ClinicalTrials.gov Identifier: NCT02430077
• Recruitment Status: Recruiting
• First Posted: April 29, 2015
• Last Update Posted: November 12, 2020
• Sponsor: University of Texas Southwestern Medical Center
• Information provided by (Responsible Party): Abhimanyu Garg, University of Texas Southwestern Medical Center

Study Description

Brief Summary:

Lipodystrophies are rare disorders characterized by selective loss of adipose tissue and predisposition to insulin resistance and its metabolic complications. Hepatic steatosis is a common complication in patients with partial and generalized lipodystrophies.Despite aggressive management of diabetes and hyperlipidemia, hepatic steatosis and its complications present a therapeutic challenge in many patients. Due to this large disease burden, it is important to assess the efficacy and safety of novel therapies for hepatic steatosis in patients with lipodystrophies.There are, however, no systematic studies evaluating various therapeutic interventions for reducing hepatic steatosis in patients with lipodystrophies. A variety of drugs have been investigated in nonlipodystrophic patients with non-alcoholic hepatic steatosis and steatohepatitis (NASH) or non-alcoholic fatty liver disease (NAFLD). Recent data support the activation of the farnesoid X receptor (FXR, NR1H4), a nuclear hormone receptor regulated by bile acids, for treatment of NASH and NAFLD. FXR activates transcription of several genes particularly the atypical nuclear receptor small heterodimer partner (SHP, NR0B2) and thus can influence triglyceride metabolism within hepatocytes.Both cholic acid (CA) and chenodeoxycholic acid (CDCA) are ligands for FXR, however, UDCA which is the 7 hydroxy β-epimer of CDCA, does not activate FXR. Obeticholic acid (OCA) is a first-in-class selective FXR agonist which has approximately 100 fold greater FXR-agonistic activity in the nanomolar range, as compared to CDCA .It therefore appears that FXR modulation offers interesting therapeutic possibilities in treating hepatic steatosis. This study is primarily designed to study efficacy of OCA, a strong FXR ligand, in reducing hepatic triglyceride levels in patients with hepatic steatosis and Familial Partial Lipodystrophy (FPLD). If proven to be effective, it may reduce morbidity and mortality as a result of sequelae of hepatic steatosis in patients with lipodystrophies.

Condition or disease	Intervention/treatment	Phase
Familial Partial Lipodystrophy	Drug: Obeticholic Acid; Drug: Placebo	Phase 2

Detailed Description:

This study will be a randomized, placebo-controlled cross-over trial. Patients who are considered eligible for the study will undergo screening evaluation to determine their eligibility for the trial. For those who are found to be eligible, during the baseline period, they will continue their usual diet and other lifestyle measures without changing any medications for 1 month in order to establish a baseline state. Three blood samples will be obtained during this period at the Clinical and Translational Research Center. Following the baseline period, the patients will receive obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months and then will receive the other treatment (OCA or placebo) for 4 months. There will be a wash-out period of 4 months in-between the two study periods.

Patients will be educated to maintain their usual physical activities and diet during the study. The subjects will be admitted to the Clinical and Translational Research Center for the baseline evaluations (at the beginning of the two study periods), and at the end of four months during each study period.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 20 participants
• Allocation: Randomized
• Intervention Model: Crossover Assignment
• Masking: Double (Participant, Investigator)
• Primary Purpose: Treatment
• Official Title: Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients
• Study Start Date: June 2016
• Estimated Primary Completion Date: May 2021
• Estimated Study Completion Date: June 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: Active capsule of Obeticholic acid; Patient will receive obeticholic acid (OCA) in the dose of 25 mg/day for a period of 4 months.	Drug: Obeticholic Acid; Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .; Other Name: NEW DRUG APPLICATION
Placebo Comparator: Pacebo for Obeticholic acid; Patient will recieve placebo in the dose of 25 mg/day for a period of 4 months.	Drug: Placebo; Identical to Obeticholic Acid - placebo drug; Other Name: Identical to Obeticholic Acid placebo drug

Outcome Measures

Primary Outcome Measures :

1. Change in the Liver Triglycerides(TG). [ Time Frame: 2 months ]
   The primary end-point variable will be the change in the liver TG content on 1H Magnetic resonance Spectroscopy (MRS).

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 70 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Patients with familial partial lipodystrophy of the Dunnigan variety with heterozygous disease-causing missense mutation in lamin A/C (LMNA) gene.
2. Hepatic steatosis (>5.6% hepatic triglyceride content) as demonstrated by 1H magnetic resonance spectroscopy.
3. Age 18-70 years.
4. Alcohol intake of less than 20 g per day in females and 30 g per day in males.
5. Participants and their partners with whom they are having sex, must use medically-acceptable birth control (contraceptives) during the study. Medically-acceptable methods of contraception include: (1) surgical sterilization, such as hysterectomy, tubal ligation or vasectomy. (2) approved hormonal contraceptives, such as birth control pills, patch or ring; Depo-Provera, Implanon. (3) barrier methods, such as condom, cervical cap or diaphragm used with a spermicide. (4) an intrauterine device (IUD).

Exclusion Criteria:

1. Laboratory or other histologic findings highly suggestive of liver disease due to causes other than non-alcoholic steatohepatitis, such as chronic viral hepatitis, autoimmune hepatitis, primary biliary cirrhosis, biliary obstruction or genetic liver diseases such as Wilson's disease, hemochromatosis or alpha-1-antitrypsin deficiency.
2. Treatment with drugs associated with steatohepatitis, e.g., corticosteroids, high dose estrogens, methotrexate, amiodarone, tamoxifen, valproic acid, sulfasalazine, or oxacillin for more than 2 weeks in the 6 months prior to the study.
3. Decompensated liver disease as evidenced by clinical features of hepatic failure (variceal bleeding, ascites, hepatic encephalopathy etc.) and laboratory investigations (prolonged prothrombin time with INR > 1.3, hypoalbuminemia with serum albumin less than 3.0 g/dL, direct bilirubin > 1.3 mg/dL, or presence of esophageal varices etc.)
4. Evidence of hepatocellular carcinoma: alpha-fetoprotein levels greater than 200 ng/ml and/or liver mass on imaging study suggestive of liver cancer.
5. Use of drugs which can potentially decrease hepatic steatosis during previous 3 months; ursodeoxycholic acid, thiazolidinediones, high-dose vitamin E, betaine, acetylcysteine and choline.
6. Significant systemic or major illnesses other than liver disease, such as congestive heart failure, cerebrovascular disease, respiratory failure, renal failure (serum creatinine >2 mg/dL), acute pancreatitis, organ transplantation, serious psychiatric disease, and malignancy, that could interfere with the trial and adequate follow up.
7. Acute medical illnesses precluding participation in the studies.
8. Known HIV-infected patient.
9. Current substance abuse.
10. Pregnant or lactating woman.
11. Hematocrit of less than 30%.
12. History of weight loss during past 3 months.
13. Patients on bile acid binding resins, cholestyramine, colestipol or colesevelam.
14. Hypersensitivity or intolerance to OCA or any components of its formulation.
15. Failure to give informed consent 16 .Previous clinical diagnosis of diabetes mellitus or fasting blood glucose ≥ 126 mg/dL or hemoglobin A1c ≥ 6.5%.

Contacts and Locations

Contacts

Contact: Claudia Quittner, RN; 214-648-9296; claudia.quittner@utsouthwestern.edu

Contact: Chandna Vasandani, Ph.D; 214-648-0550; chandna.vasandani@utsouthwestern.edu

Locations

United States, Texas

UT Southwestern Medical Center 5323 Harry Hines Blvd; Recruiting

Dallas, Texas, United States, 75390-8537

Contact: Claudia Quittner, RN claudia.quittner@utsouthwestern.edu

Contact: Chandna Vasandani, Ph.D 214-648-5074 chandna.vasandani@utsouthwestern.edu

Principal Investigator: Abhimanyu Garg, MD

Sub-Investigator: Zahid Ahmad, M.D.

UT Southwestern Medical Center 5323 Harry Hines Blvd; Recruiting

Dallas, Texas, United States, 75390-8537

Principal Investigator: Abhimanyu Garg, MD

Sub-Investigator: Zahid Ahmad, M.D.

UT Southwestern Medical Center; Recruiting

Dallas, Texas, United States, 75390

Contact: Claudia Quittner, RN 214-648-9296 claudia.quittner@utsouthwestern.edu

Sponsors and Collaborators

University of Texas Southwestern Medical Center

Investigators

• Principal Investigator: Abhimanyu Garg, MD; UT Southwestern Medical Center

More Information

• Responsible Party: Abhimanyu Garg, PROFESSOR, Internal Medicine, University of Texas Southwestern Medical Center
• ClinicalTrials.gov Identifier: NCT02430077
• Other Study ID Numbers: STU 062014-033
• First Posted: April 29, 2015
• Last Update Posted: November 12, 2020
• Last Verified: May 2020

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Keywords provided by Abhimanyu Garg, University of Texas Southwestern Medical Center:

Hepatic Steatosis

Additional relevant MeSH terms:

Lipodystrophy; Lipodystrophy, Familial Partial; Skin Diseases, Metabolic; Skin Diseases; Lipid Metabolism Disorders; Metabolic Diseases; Chenodeoxycholic Acid; Cathartics; Gastrointestinal Agents